Lymphocyte function-associated antigen 1 (LFA-1) antagonist

GPTKB entity

Statements (53)
Predicate Object
gptkbp:instance_of gptkb:antagonist
gptkbp:administered_by injection
gptkbp:affects T cell activation
B cell function
gptkbp:application autoimmune diseases
inflammatory diseases
gptkbp:associated_with chronic diseases
gptkbp:benefits reducing inflammation
gptkbp:can_be_combined_with other therapies
biologics
gptkbp:can_be_used_to cancer therapy
combination therapy
gptkbp:can_cause adverse reactions
gptkbp:clinical_trial ongoing
gptkbp:developed_by biopharmaceutical companies
treatment of diseases
gptkbp:discovered_by laboratory studies
gptkbp:enhances patient quality of life
therapeutic efficacy
treatment outcomes
immune checkpoint blockade
vaccine responses
gptkbp:facilitates immune tolerance
gptkbp:has_influence_on disease progression
https://www.w3.org/2000/01/rdf-schema#label Lymphocyte function-associated antigen 1 (LFA-1) antagonist
gptkbp:impact chronic inflammatory conditions
gptkbp:influences cytokine production
lymphocyte migration
gptkbp:inhibits_binding LFA-1 to ICAM-1
gptkbp:initiated_by cell adhesion
T cell proliferation
monocyte adhesion
gptkbp:interacts_with other immune modulators
gptkbp:involved_in cell signaling pathways
immune response modulation
gptkbp:is_effective_against certain cancers
gptkbp:is_part_of personalized medicine approaches
gptkbp:is_studied_in animal models
gptkbp:may_alter immune cell trafficking
gptkbp:may_be_evaluated_in clinical settings
gptkbp:may_be_investigated_for new indications
gptkbp:mechanism_of_action blocking LFA-1 interaction
gptkbp:reduces symptoms of diseases
autoimmune reactions
gptkbp:related_to integrins
gptkbp:research_focus therapeutic agents
gptkbp:role transplant rejection prevention
gptkbp:side_effect immune suppression
gptkbp:targets LFA-1
gptkbp:used_in clinical research
immunology
gptkbp:bfsParent gptkb:Xiidra
gptkbp:bfsLayer 6